Cargando…

A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity

Tumor heterogeneity remains a major challenge for disease subtyping, risk stratification, and accurate clinical management. Exosome-based liquid biopsy can effectively overcome the limitations of tissue biopsy, achieving minimal invasion, multi-point dynamic monitoring, and good prognosis assessment...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Fei, Ma, Haodong, Hao, Youjin, Tian, Luyao, Li, Yinghong, Li, Bo, Chen, Juan, Tang, Ying, Li, Jing, Deng, Lili, Xie, Guoming, Liu, Mingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232662/
https://www.ncbi.nlm.nih.gov/pubmed/37273850
http://dx.doi.org/10.1016/j.csbj.2023.05.013
_version_ 1785052036125949952
author Long, Fei
Ma, Haodong
Hao, Youjin
Tian, Luyao
Li, Yinghong
Li, Bo
Chen, Juan
Tang, Ying
Li, Jing
Deng, Lili
Xie, Guoming
Liu, Mingwei
author_facet Long, Fei
Ma, Haodong
Hao, Youjin
Tian, Luyao
Li, Yinghong
Li, Bo
Chen, Juan
Tang, Ying
Li, Jing
Deng, Lili
Xie, Guoming
Liu, Mingwei
author_sort Long, Fei
collection PubMed
description Tumor heterogeneity remains a major challenge for disease subtyping, risk stratification, and accurate clinical management. Exosome-based liquid biopsy can effectively overcome the limitations of tissue biopsy, achieving minimal invasion, multi-point dynamic monitoring, and good prognosis assessment, and has broad clinical prospects. However, there is still lacking comprehensive analysis of tumor-derived exosome (TDE)-based stratification of risk patients and prognostic assessment for breast cancer with systematic dissection of biological heterogeneity. In this study, the robust corroborative analysis for biomarker discovery (RCABD) strategy was used for the identification of exosome molecules, differential expression verification, risk prediction modeling, heterogenous dissection with multi-ome (6101 molecules), our ExoBCD database (306 molecules), and 53 independent studies (481 molecules). Our results showed that a 10-molecule exosome-derived signature (exoSIG) could successfully fulfill breast cancer risk stratification, making it a novel and accurate exosome prognostic indicator (Cox P = 9.9E-04, HR = 3.3, 95% CI 1.6–6.8). Interestingly, HLA-DQB2 and COL17A1, closely related to tumor metastasis, achieved high performance in prognosis prediction (86.35% contribution) and accuracy (Log-rank P = 0.028, AUC = 85.42%). With the combined information of patient age and tumor stage, they formed a bimolecular risk signature (Clinmin-exoSIG) and a convenient nomogram as operable tools for clinical applications. In conclusion, as an extension of ExoBCD, this study conducted systematic analyses to identify prognostic multi-molecular panel and risk signature, stratify patients and dissect biological heterogeneity based on breast cancer exosomes from a multi-omics perspective. Our results provide an important reference for in-depth exploration of the "biological heterogeneity - risk stratification - prognosis prediction".
format Online
Article
Text
id pubmed-10232662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-102326622023-06-02 A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity Long, Fei Ma, Haodong Hao, Youjin Tian, Luyao Li, Yinghong Li, Bo Chen, Juan Tang, Ying Li, Jing Deng, Lili Xie, Guoming Liu, Mingwei Comput Struct Biotechnol J Research Article Tumor heterogeneity remains a major challenge for disease subtyping, risk stratification, and accurate clinical management. Exosome-based liquid biopsy can effectively overcome the limitations of tissue biopsy, achieving minimal invasion, multi-point dynamic monitoring, and good prognosis assessment, and has broad clinical prospects. However, there is still lacking comprehensive analysis of tumor-derived exosome (TDE)-based stratification of risk patients and prognostic assessment for breast cancer with systematic dissection of biological heterogeneity. In this study, the robust corroborative analysis for biomarker discovery (RCABD) strategy was used for the identification of exosome molecules, differential expression verification, risk prediction modeling, heterogenous dissection with multi-ome (6101 molecules), our ExoBCD database (306 molecules), and 53 independent studies (481 molecules). Our results showed that a 10-molecule exosome-derived signature (exoSIG) could successfully fulfill breast cancer risk stratification, making it a novel and accurate exosome prognostic indicator (Cox P = 9.9E-04, HR = 3.3, 95% CI 1.6–6.8). Interestingly, HLA-DQB2 and COL17A1, closely related to tumor metastasis, achieved high performance in prognosis prediction (86.35% contribution) and accuracy (Log-rank P = 0.028, AUC = 85.42%). With the combined information of patient age and tumor stage, they formed a bimolecular risk signature (Clinmin-exoSIG) and a convenient nomogram as operable tools for clinical applications. In conclusion, as an extension of ExoBCD, this study conducted systematic analyses to identify prognostic multi-molecular panel and risk signature, stratify patients and dissect biological heterogeneity based on breast cancer exosomes from a multi-omics perspective. Our results provide an important reference for in-depth exploration of the "biological heterogeneity - risk stratification - prognosis prediction". Research Network of Computational and Structural Biotechnology 2023-05-12 /pmc/articles/PMC10232662/ /pubmed/37273850 http://dx.doi.org/10.1016/j.csbj.2023.05.013 Text en © 2023 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Long, Fei
Ma, Haodong
Hao, Youjin
Tian, Luyao
Li, Yinghong
Li, Bo
Chen, Juan
Tang, Ying
Li, Jing
Deng, Lili
Xie, Guoming
Liu, Mingwei
A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
title A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
title_full A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
title_fullStr A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
title_full_unstemmed A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
title_short A novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
title_sort novel exosome-derived prognostic signature and risk stratification for breast cancer based on multi-omics and systematic biological heterogeneity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232662/
https://www.ncbi.nlm.nih.gov/pubmed/37273850
http://dx.doi.org/10.1016/j.csbj.2023.05.013
work_keys_str_mv AT longfei anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT mahaodong anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT haoyoujin anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT tianluyao anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT liyinghong anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT libo anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT chenjuan anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT tangying anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT lijing anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT denglili anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT xieguoming anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT liumingwei anovelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT longfei novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT mahaodong novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT haoyoujin novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT tianluyao novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT liyinghong novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT libo novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT chenjuan novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT tangying novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT lijing novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT denglili novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT xieguoming novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity
AT liumingwei novelexosomederivedprognosticsignatureandriskstratificationforbreastcancerbasedonmultiomicsandsystematicbiologicalheterogeneity